Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Merck announced that first-time Phase 3 results from three pivotal oncology trials will be presented in late-breaking ESMO Presidential Symposia, including INTerpath-001 showing intismeran autogene plus KEYTRUDA improved recurrence-free and distant metastasis-free survival versus KEYTRUDA alone in resected stage IIB-IV melanoma. TroFuse-005 demonstrated the first Phase 3 overall survival and progression-free survival improvement for a TROP2-directed ADC in certain advanced or recurrent endometrial cancer patients, and KEYNOTE-C93 supported first-line KEYTRUDA monotherapy in dMMR endometrial cancer. More than 90 additional abstracts across over 20 tumor types will also be presented.
Key figures
- Investor event
- Oncology Investor Event Oct 26, 2026, webcast from Madrid
- Tro Fuse patients
- more than 15,000
- Tumor types covered
- more than 20
- Additional abstracts
- more than 90
- Presidential symposia
- 3
- Tro Fuse phase3 trials
- 18
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.